China’s brain-computer interface industry is racing ahead
#brain-computer interface #China #NeuroXess #Gestala #Neuralink #clinical trials #medical insurance #ultrasound BCI
📌 Key Takeaways
- China's BCI industry is rapidly advancing from research to commercialization with strong government support
- Four key factors driving China's BCI acceleration: policy support, clinical resources, manufacturing capabilities, and strategic investment
- China's BCI market is projected to grow from 3.2 billion yuan in 2024 to over 120 billion yuan by 2040
- The industry encompasses both invasive and non-invasive approaches, with emerging ultrasound technologies showing promising clinical results
- China's national health insurance system enables faster commercialization compared to fragmented insurance markets in other countries
📖 Full Retelling
China's brain-computer interface industry, led by startups like NeuroXess and Gestala founded by serial entrepreneur Phoenix Peng, is rapidly advancing from research to commercialization across provinces including Sichuan, Hubei, and Zhejiang in 2025, propelled by robust government support, expanding clinical trials, and surging investor interest in this transformative technology. The Chinese BCI sector is experiencing unprecedented growth as both implantable and non-invasive technologies move toward market readiness. Unlike Neuralink's more publicized efforts in the United States, China's approach has been characterized by methodical progress with concrete policy backing. In August 2025, China's industry ministry and six other agencies released a national roadmap targeting major technical milestones by 2027, common industry standards, and a complete supply chain by 2030. Four key factors are driving China's BCI acceleration: strong policy support with cross-departmental collaboration, vast clinical resources enabling faster trials, mature industrial manufacturing capabilities, and strategic investment from both state-led funds and private capital. In December 2025, China announced an 11.6 billion yuan ($165 million) brain science fund specifically to support BCI companies through the commercialization process. China's BCI landscape encompasses two primary technological paths: invasive electrophysiological systems like NeuroXess that implant electrodes for precise neuron-level signals, and non-invasive solutions like BrainCo that prioritize safety and ease of use. Emerging approaches, including ultrasound-based technologies from companies like Gestala, are targeting high-precedence conditions such as chronic pain, stroke, and depression, with early clinical trials showing promising results including 50% pain reduction after a single session.
🏷️ Themes
Technological Innovation, Healthcare Advancement, Market Growth, Policy Development
📚 Related People & Topics
Neuralink
American neurotechnology company
Neuralink Corp. is an American neurotechnology company that has developed as of 2024 implantable brain–computer interfaces (BCIs). It was founded by Elon Musk and a team of eight scientists and engineers.
China
Country in East Asia
China, officially the People's Republic of China (PRC), is a country in East Asia. It is the second-most populous country after India, with a population exceeding 1.4 billion, representing 17% of the world's population. China borders fourteen countries by land across an area of 9.6 million square ki...
Entity Intersection Graph
No entity connections available yet for this article.
Deep Analysis
Original Source
While Elon Musk’s Neuralink likes to say it’s “ pioneering ” brain-computer interfaces , China’s BCI industry is already quietly moving from research to scale. A new wave of startups is racing to commercialize both implantable and noninvasive BCIs, backed by stronger policy support, expanding clinical trials, and growing investor interest. So says Phoenix Peng, who has founded not one, but two BCI startups. He’s a co-founder of NeuroXess, maker of BCI implants, as well as founder and CEO of noninvasive ultrasound BCI startup Gestala. His belief in the potential of this market is founded on concrete action: Provinces such as Sichuan, Hubei, and Zhejiang have already set medical service pricing for BCI, speeding its inclusion in the national medical insurance system. Over time, he foresees the technology extending beyond medicine “treating disease” to “human augmentation,” he said. “I have always maintained that neuroscience and AI are two sides of the same coin. They are destined for deep integration, realizing direct high-bandwidth connections between the human brain and AI. BCI will serve as the ultimate bridge between carbon-based and silicon-based intelligence. While this may sound distant, it represents an unimaginably vast market in the future,” Peng said. Four factors driving BCI in China But over the next three to five years, BCI use is likely to stay concentrated in healthcare, with the market reaching multibillion-dollar scale as insurance coverage expands, Peng told TechCrunch. In August 2025, China’s industry ministry and six other agencies released a national roadmap to further speed development of BCIs. The plan targets major technical milestones by 2027, common industry standards, and a full supply chain by 2030, with the goal of building globally competitive BCI companies and supporting smaller specialized firms. Techcrunch event Save up to $300 or 30% to TechCrunch Founder Summit 1,000+ founders and investors come together at TechCrunch Founder Summi...
Read full article at source